New Class of Antigen-Specific Cancer Active Immunotherapies Based on a Potent Presenting Cell Line (PDC*line)
Time: 5:30 pm
day: Conference Day One
Details:
- PDC*line is a new potent and scalable therapeutic cancer vaccine based on a proprietary allogeneic cell line of plasmacytoid dendritic cells
- Presentation of the first results of the ongoing phase I/II clinical trial for NSCLC patients
- Initiation of a phase Ib clinical trial with a personalized neoantigen-based vaccine in CRC patients
